Know Labs Q3 net loss $3.59M, EPS loss $0.07, cash $3.93M, expects to fund through Dec 2023

USBC, Inc.

Net loss of $3.59M in Q3 FY2023 vs $3.03M year ago; EPS loss $0.07 unchanged.
Cash dropped to $3.93M from $12.59M at Sept 30, 2022; net cash used in ops $8.97M in 9 months.
R&D expense rose to $1.87M from $1.27M YoY on Gen1 device development; SG&A fell to $1.35M.
Completed Gen1 non-invasive glucose monitor on June 7, 2023; path to FDA trials and commercialization.
Company expects to raise additional funds via preferred stock, convertible debentures, and equity in 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

USBC, Inc. reported third quarter ended June 30, 2023 results: net income net loss of $3.59 million dollars, EPS loss of $0.07.

Period: third quarter ended June 30, 2023
Net income: net loss of $3.59 million dollars
EPS: loss of $0.07
Result: reported results

Exact text from the filing

Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

USBC, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-010993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.